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Abstract
Elesclomol is a first-in-class investigational drug currently undergoing clinical evaluation as a novel cancer therapeutic. The
potent antitumor activity of the compound results from the elevation of reactive oxygen species (ROS) and oxidative stress
to levels incompatible with cellular survival. However, the molecular target(s) and mechanism by which elesclomol
generates ROS and subsequent cell death were previously undefined. The cellular cytotoxicity of elesclomol in the yeast S.
cerevisiae appears to occur by a mechanism similar, if not identical, to that in cancer cells. Accordingly, here we used a
powerful and validated technology only available in yeast that provides critical insights into the mechanism of action,
targets and processes that are disrupted by drug treatment. Using this approach we show that elesclomol does not work
through a specific cellular protein target. Instead, it targets a biologically coherent set of processes occurring in the
mitochondrion. Specifically, the results indicate that elesclomol, driven by its redox chemistry, interacts with the electron
transport chain (ETC) to generate high levels of ROS within the organelle and consequently cell death. Additional
experiments in melanoma cells involving drug treatments or cells lacking ETC function confirm that the drug works similarly
in human cancer cells. This deeper understanding of elesclomol’s mode of action has important implications for the
therapeutic application of the drug, including providing a rationale for biomarker-based stratification of patients likely to
respond in the clinical setting.
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Introduction
Elesclomol is a novel small molecule drug originally identified in
a cell-based screen for its potent proapoptotic activity in cancer
cells. More recently, in vitro studies indicated that it strongly
induces reactive oxygen species (ROS) within tumor cells [1],
leading to unmanageable levels of oxidative stress and consequent
apoptosis. However, the cellular target of elesclomol remained
unknown, as did the molecular mechanism by which it generated
ROS.
Increased levels of ROS and an altered redox status have long
been observed in cancer cells [2], where constitutively elevated
oxidative stress and dependence on antiapoptotic ROS signaling
represent potential vulnerabilities of tumors that can be exploited
by small molecule drugs [3]. To test its usefulness as a therapeutic,
elesclomol has been evaluated in human clinical studies [4,5] and
combined data from three randomized Phase 2 and 3 trials have
demonstrated therapeutic benefit, including prolonged progres-
sion-free survival, in a subset of the patients treated [6].
Interestingly, this subset was distinguished by the prevalence of
subjects with low baseline levels of serum lactate dehydrogenase
(LDH). LDH level is known as a prognostic marker for outcome in
cancer, but for elesclomol, it also appears also to be a predictive
marker of efficacy [6]. Understanding the relationship between
clinical benefit and serum LDH level at a molecular level would
greatly assist the continued clinical development of the drug,
including the identification of patients most likely to benefit.
As part of the continuing effort to better understand elesclomol’s
cellular mechanism of action (MoA), Nagai et al. found that the
compound binds strongly to copper (Figure 1A) and that this
binding is required for its cell killing activity [7]. When
administered to humans, elesclomol acquires the needed copper
ions (in the form of Cu
2+) while in the bloodstream. Copper
binding changes the conformation of the drug [8], facilitates its
uptake into cells, and allows it to undergo redox cycling [Cu(II) to
Cu(I)] to generate ROS inside the cell [7]. In the absence of bound
copper, the compound has no discernible activity.
To further refine elesclomol’s MoA, we made use of a powerful
comparative growth assay available in the yeast Saccharomyces
cerevisiae. While performed in yeast, this strategy has in previous
studies (particularly for cancer drugs) identified relevant mecha-
nistic details that are indicative of the drugs’ actions in humans
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29798[9,10,11,12,13]. The assay uses a set of diploid yeast strains that
were systematically constructed such that each strain contains a
single start-to-stop gene deletion and that the set en toto contains a
deletion mutant for each yeast gene [14,15]. For the ,1100 genes
that are essential for growth (in the medium employed here), those
mutant strains are screened as heterozygotes. The remaining
,4800 strains, containing mutations in non-essential genes, are
screened as homozygotes. In practice, these yeast strains are grown
in the presence of the drug of choice, here elesclomol, at sub-lethal
doses. Deletion mutations that render the cell more sensitive to
treatment serve to elucidate the MoA of the drug (for review, see
[16]). For example, if the target of the drug is an essential protein in
the cell, its corresponding heterozygous strain is likelyto be the most
growth-impaired in the collection. Similarly, analysis of the
homozygous knockout strains identifies genes whose protein
products are required for unabated growth when challenged with
the compound. Together these screens identify the pathways
associated with the drug target and the mechanisms the cell uses
to counter the drug’s effects [9,17]. A critical element of this
methodologyisthat each strainalsocontainsa ‘‘molecular barcode’’
sequence in its genome that serves as a unique strain identifier [18].
Because the strains are barcoded, the entire collection of strains can
be pooled and treated simultaneously with the drug. At the end of
the experiment, the abundance of each barcode is quantified in
parallel using Affymetrix gene chip technology such that the growth
characteristics of all 6000 strains are simultaneously determined
(Figure S1). The feasibility and effectiveness of this system has been
demonstrated previously by screening well-characterized and novel
compounds [10,11,12,18,19,20,21,22].
Using this strategy, we found that elesclomol does not work
through a specific cellular protein target, but rather works
primarily by influencing redox reactions associated with the
mitochondrial electron transport chain (ETC). This disruption
leads to increased levels of ROS in the organelle and subsequently
to cell death. We also show that this mechanism is conserved
between yeast and human cancer cells. Taken together, these
results provide a convincing explanation for the efficacy of
elesclomol in low LDH patients, and support a strategy of patient
stratification in future clinical work with the drug.
Results
Yeast are sensitive to elesclomol treatment only in the
presence of copper
We initially examined whether elesclomol treatment affected
the growth of yeast. Because in mammalian cells elesclomol is
only active when bound to copper [7], we performed the growth
analysis of the wild-type BY4743 strain (the parent of the deletion
strains) in the presence of elesclomol alone, elesclomol plus varying
concentrations of copper chloride (CuCl2), or with preformed
elesclomol-Cu complex (Figure 1B). The cultures with elesclomol
plus copper or elesclomol-Cu showed potent growth inhibition
Figure 1. Elesclomol-induced ROS generation and cytoxicity in yeast is dependent on the presence of copper. (A) Chemical structure
of the elesclomol-Cu complex. (B) The parental BY4743 yeast strain was grown in the presence of the indicated concentrations of elesclomol,
preformed elesclomol-Cu, and/or copper for 21.5 h at 30uC. Absorbance at 600 nm was used to determine cell density. (C) Flow cytometric analysis
measuring ROS in S. cerevisiae. ROS induction, as measured by Dihydrorhodamine 123 fluorescence, was only observed with preformed elesclomol-Cu
complex at a concentration (500 nM) above the MIC but not below (100 nM), nor with free elesclomol at either concentration (upper panel). The
addition of supplementary copper (via CuCl2) to elesclomol was sufficient to induce ROS, again only at the higher concentration (lower panel).
(D) Elesclomol is cidal to yeast cells within an hour of treatment. Logarithmically growing cells were incubated with the indicated doses of elesclomol
for 1, 2 or 4 h and then plated onto media without elesclomol. 5 mM and 22.5 mM elesclomol rendered cells unviable within 1 h, and lower doses
(1.25 mM) killed cells within 4 h.
doi:10.1371/journal.pone.0029798.g001
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500 nM range. Elesclomol supplemented with copper at concen-
trations from 10 mM to 1 mM all yielded the same MIC (data not
shown). In contrast, elesclomol without added copper had no effect
on yeast growth at concentrations up to 200 mM, while CuCl2 on
its own had no effect at concentrations up to 2 mM, the latter
consistent with a previous report [23].
Given the requirement for copper to induce ROS in cultured
cells, we also tested whether elesclomol plus copper could induce
ROS in yeast (Figure 1C). As with mammalian cells, ROS was
strongly induced only in the presence of copper (either by copper
supplement or as part of a preformed complex), but only at
concentrations above the MIC. No ROS was observed at 100 nM
elesclomol plus copper or elesclomol-Cu, consistent with ROS
induction being required for growth inhibition.
Finally, we tested whether elesclomol treatment led to cell death
(cidality) or simply growth arrest. Specifically, we grew wild type
cells with elesclomol-Cu at varying concentrations for 1 to 4 hours
with constant shaking at 30uC. Following treatment, cells were
washed in fresh media and spotted onto solid growth medium
without drug (Figure 1D). Elesclomol-Cu at 1.25 mM prevented
colony formation after 3 h of treatment, while 2.5 mM was cidal
after 1 h exposure. Taken together, these results show that
elesclomol in the presence of copper, but not alone, potently kills
cells after strongly inducing ROS.
There is no cellular protein target for elesclomol
Given the conserved nature of the responses to elesclomol
treatment, we reasoned that a comprehensive screen of the yeast
deletion collection could reveal detailed insights into elesclomol’s
mechanism of action in both yeast and mammalian cells. For our
assays, we used sub-MIC doses of 300 and 400 nM elesclomol-Cu,
concentrations that were determined empirically to inhibit growth
of the BY4743 strain by 10–20% under the conditions of the
library screening. Triplicate biological replicates were then
performed at both doses. An analysis of the data (the log2 ratio
of the normalized strain signal in treatment vs. DMSO control)
showed that the results were similar at both drug concentrations,
so we combined all six datasets by averaging the log2 ratios to yield
a single set of responses (Table S1). The combined values were
used for all analyses presented here.
As we showed previously for other drugs, if elesclomol affects
cell growth by interacting or interfering with a specific protein in
the cell (i.e., its protein target), we expect that the heterozygous
strain deleted for that gene would be highly sensitive to the drug
treatment [10,11]. In the plot shown in Figure 2A, the further up
the y-axis, the more sensitive the strain, with the most sensitive
strain representing the likely drug target [10]. In our experiments,
the nus1 deletion strain was the only heterozygous deletion strain
that scored as sensitive (log2 ratio .2). NUS1 encodes a putative
prenyltransferase implicated in intracellular trafficking. However,
the magnitude of the strain’s sensitivity to elesclomol was modest
compared to other drug-target combinations we have analyzed in
the past [12,24]. Moreover, the nus1 heterozygote manifests a
general sensitivity to a variety of compounds and conditions [12],
suggesting that its sensitivity to elesclomol-Cu is not target related.
Taken together, these data support the idea that yeast lack a
specific protein target through which elesclomol exerts its cytotoxic
activity.
Elesclomol targets electron transport activity in the
mitochondrion
In contrast, the sensitive strains among the homozygous deletions
formed a biologically coherent set, consistent with elesclomol
interacting with a specific target pathway (Figure 2B). Nearly all of
the 48 strains with a log2 ratio .2 have a role in mitochondrial
function (Table S1). At a less stringent log2 ratio cut-off of 1.1,
,80% of the 190 genes are involved in mitochondrial activities.
Closer inspection of these 190 reveals several interesting classes of
genes. Notably, genes that are involved in diverse functions of
electron transport, including structural components of the ETC
(PET309, COB1, SHY1, COQ10, YER077C, COX12, COX9, QCR2,
CYT1, BCS1, COQ9, QCR7) or involvement in the translation,
modification or assembly of cytochrome components (OXA1, CBT1,
COX20, PET54, MNE1, CYT2, COQ9, COX16, CBP2, PET117,
COX18) showed sensitivity. In addition, 7 structural components of
the F1F0 ATPase were sensitive as deletion alleles (ATP1,4,7,10,
11,12,17). Several genes that comprise the mitochondrial ribosome
or are directly involved in translation were identified, including:
PET123, MRPL28,23,17,31,51,27,11,38,33 RSM22,19, IFM1,
MTG2, MRPS16,17, and MEF2 as well as 7 of the 24 mitochondrial
tRNA genes (MSM1, MSE1, MSY1, MSD1, MSF1, HER2, TPT1).
The loss of these components would likely impair the production of
the mitochondrially-encoded components of the ETC. Genes
involved in copper-related functions were also identified, including
COX23, an inner mitochondrial membrane required for copper
homeostasis and cytochrome oxidase expression; COX11 which is
required for delivery of copper to the Cox1p subunit of cytochrome
oxidase; COX 17, a mitochondrial copper metallochaperone; and
CUP2, a nuclear transcriptionfactor that is activated in the presence
of copper. Finally, genes involved in the oxidative stress response
were also sensitive as deletion strains, including several whose
proteins are located within mitochondria: SOD2 (the mitochondrial
superoxidedismutase),POS5, MGM101,PRE6,UTH1,an dFMP46;
as well as several reported to be present in the cytoplasm: APD1,
OCA1, RIM11, CNB1, YFR039C, HSP150 and CCH1. Interestingly,
deletion of SOD1, the cytoplasmic superoxide dismutase, was not
sensitizing, but rather conferred a degree of resistance (see
discussion below).
To examine the yeast data more systematically, the entire
dataset was analyzed by gene-set enrichment analysis (GSEA) [25].
GSEA provides an algorithmic tool to identify pathways and
processes whose components are over-represented among the
sensitive strains. This analysis evaluates all processes of the cell,
and the only ‘‘supergroups’’ (major nodes) identified as signifi-
cantly enriched are depicted in Figure 3A. The supergroup clusters
in the figure highlight the connections between enriched functions
within its biological category (with the connection strength
indicated by the width of the lines connecting the functions). For
each supergroup, the top 10 genes (or fewer in cases where fewer
than 10 genes comprise that function) of the core gene set that is
responsible for the enrichment score are shown in the histograms
(Figure 3B) (see legend for details). The enriched clusters include:
respiration complexes and respiration, mitochondrial membrane
localization, mitochondrial tRNAs, mitochondrial genome main-
tenance, transport into/out of the mitochondria, splicing of
mitochondrial transcripts, and metal ion homeostasis (Figure 3).
Given that this analysis encompasses all biological processes and
pathways described for the cell, it is striking that the only ones
identified as significantly over-represented in our dataset involve
mitochondrial processes or copper-related activities.
Elesclomol works by a distinct mechanism of action
The cellular response to elesclomol identified by the subset of
sensitive strains provides a unique fingerprint of the system-level
response to the drug. To quantify this observation, we compared
the elesclomol profile to over 3,000 drug profiles (including 300
FDA approved drugs; [26]) in our database (publicly available at
Elesclomol Targets Mitochondrial ETC to Induce ROS
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confirmed that the elesclomol profile was unique. In fact the most
correlated profile showed only a modest similarity, r
2=0.55.
These heretofore uncharacterized compounds were derived from a
synthetic compound library from ChemDiv Laboratories (San
Diego, CA; compound IDs: 0352-0636, 0141-0289, 0269-0018).
In contrast to the elesclomol profile, these 3 compounds show
enrichment for genes primarily involved in mitochondrial protein
synthesis (see http://chemogenomics.med.utoronto.ca/supplemen-
tal/elesclomol/). These data strongly suggest that elesclomol acts by
a novel mechanism not shared by any previously tested compound.
Notably, we previously examined the profile produced by
overloading the cell with copper, i.e., growth in the presence of
10 mM CuCl2 [27]. The only overlap in the most sensitive strains
from this treatment and that produced by elesclomol-Cu was the
hypersensitivity of the cup2 homozygous deletion strain. This rather
limited overlap presumably reflects the fact that copper overload in
yeast is only seen at concentrations 25,000 fold greater than that
used here for elesclomol-Cu (10 mM vs. 400 nM). This strongly
suggests that the cellular activity of the elesclomol-Cu complex is
entirely distinct from that produced solely by copper toxicity.
Elesclomol interacts similarly with the ETC in human cells
Among our sensitive yeast strains, combinations of elesclomol
with specific gene deletion mutations led to greater growth
impairment than would result from either insult alone. A similar
approach is often undertaken with drug characterization in
mammalian cells, whereby a second drug is used to examine
whether co-treatment leads to synergistic effects on activity. The
yeast data identified mitochondrial activities, and the ETC in
particular, as processes affected by elesclomol. To determine
whether this requirement for mitochondrial function and an intact
ETC is conserved from yeast to human, we tested elesclomol-Cu
in combination with the known ETC inhibitors antimycin A (a
Figure 2. Sensitivity of S. cerevisiae mutant strains to elesclomol-Cu. (A) A genome-wide readout of heterozygous strain sensitivity. In the
plot, the X-axis orders all genes by their systematic name (hence, chromosome position) while the Y-axis is a measure of the ‘fitness’ of the strain
deleted for the indicated gene grown in sub-lethal doses of elesclomol-Cu. The value on the Y-axis corresponds to 2log2 (ratio of normalized strain
signal in treatment to DMSO control). Hence, the zero line represents equivalent growth in both conditions, while each unit above the line represents
a 2-fold reduction in strain fitness. (B) Genome-wide profile of homozygous strain sensitivity. The data are presented as in (A). Among the 150 most
sensitive strains, the 137 having mitochondrial roles are highlighted color-coded: red (7 genes, mitochondrial genome maintenance), dark brown (8
genes, metal ion homeostasis), bright green (26 genes, mitochondrial localization), aqua (4 genes, mitochondrial, uncharacterized), blue (36 genes,
ox-phos and respiration) mauve (5 genes, mitochondrial splicing), light gray (9 genes, response to stress) dark brown (26 genes, mitochondrial
translation), dark gray (7 genes, mitochondrial import/export) and dark green (9 genes, mitochondrial tRNA).
doi:10.1371/journal.pone.0029798.g002
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human melanoma cells (Hs294T). As single agents, both ETC
inhibitors were cytotoxic, although their dose response curves were
broad in comparison to the steep curve exhibited by elesclomol-Cu
(Figure 4A). Concurrent administration of IC20 doses of elesclo-
mol-Cu with antimycin A or rotenone resulted in substantial
Figure 3. Biological processes and protein complexes associated with sensitivity to elesclomol. (A) Each node represents a significantly
enriched biological process/protein complex in the elesclomol chemogenomic profile as determined by GSEA. The size of a node corresponds to the
number of genes annotated to the functional category. The width of an edge corresponds to the level of gene overlap between two interconnected
categories (i.e. gene sets). Edges are not shown where the overlap coefficient is less than 0.5 (see Materials and Methods). The color of a node shows
the cluster membership where clustering is based on the level of overlap between categories. (B) Each bar plot corresponds to the cluster indicated
by its border color, and shows the individual sensitivity scores (X-axis) of the genes that contributed to the functional enrichments of the cluster. For
clusters with more than 10 genes contributing to the enrichments, only the top 10 associated with the most categories are shown. The percentage of
times the particular genes occur in that gene set is indicated by a color key, with black indicating the gene is present every time that function appears
enriched, graded to white for those genes in the leading edge that appear less frequently within the gene set.
doi:10.1371/journal.pone.0029798.g003
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torial benefit was also seen at IC50 doses (Figure 4B, 4C). A more
extensive set of combinations, analyzed by the Chou-Talalay
method based on the median effect equation [28], also showed
substantial enhancement of activity with either drug upon co-
administration with elesclomol (Figure S2). Although a precise
quantitation of synergy is confounded by the differences in the
degrees of dose response (as reflected in the shapes of the dose
response curves), these results show that direct modulation of the
ETC and mitochondrial respiration in human cells enhances the
cytotoxic activity of elesclomol.
Human cells lacking ETC activities are insensitive to
elesclomol
Further evidence of a conserved MoA is provided by
experiments using human HBL melanoma cells either containing
their mitochondrial DNA (parent cells) or devoid of it (HBL-r0)
[29]. Without the mitochondrial DNA, HBL-r0 cells cannot
perform electron transport or oxidative phosphorylation, although
other mitochondrial functions are maintained. HBL and HBL-r0
cells were treated with 300 nM elesclomol-Cu for 12 h and
superoxide generation determined using a fluorescent probe
(hydroxyethidium) for ROS generation. As shown in Figure 5A,
ROS was readily observed in the parental cells but not in the
deficient HBL-r0 line, indicating that elesclomol-Cu requires a
functioning ETC to induce ROS. Similarly, elesclomol-Cu
potently induced mitochondria-mediated cell death by 24 h in
the HBL cells but not in the HBL-r0 cells (Figure 5B). Copper
treatment alone had no effect under any of these conditions.
Taken together, these findings strongly suggest that elesclomol-Cu-
induced ROS generation directly translates to apoptotic effects,
with both these activities dependent on the integrity of the
mitochondrial ETC.
Discussion
In a previous study on elesclomol’s mechanism of action [1], the
drug was shown to accomplish its cancer killing activity via the
induction of untenable levels of intracellular ROS followed by
apoptosis. The cellular mechanism and target by which this
occurred, however, remained unknown. In those studies, mito-
chondrial involvement was specifically ruled out on the basis of
using isolated mitochondria. However these experiments were
performed in the absence of copper rendering them uninforma-
tive. In this study, with the importance of copper newly realized
[7], we have used an in vivo yeast system and additional in vitro
human cell studies to identify the mitochondrion as the source of
elesclomol-induced ROS and strongly implicate the process of the
electron transport as the ‘‘target’’ of the drug.
As we have shown for other cancer drugs [9,10,12,17], the
approach of using the yeast deletion collection yielded an accurate
indication of elesclomol’s mechanism of action in mammalian
cancer cells. This is predicated on the similarities of the cellular
responses in these different eukaryotic cells, which we found to be
Figure 4. Combinations of elesclomol-Cu and ETC complex inhibitors in melanoma cells. (A) Single agent viability assays in Hs249T
human melanoma cells using graded concentrations of elesclomol-Cu, antimycin A or rotenone for 72 h. The IC50 values obtained were 11 nM,
240 nM and 77 nM, respectively. Combination treatment of elesclomol-Cu with antimycin A (B) or rotenone (C) at IC20 or IC50 doses resulted in
significantly enhanced cytotoxicity, showing that direct modulation of the ETC and mitochondrial respiration in mammalian cells enhances the
cellular activity of elesclomol.
doi:10.1371/journal.pone.0029798.g004
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require copper for elesclomol activity, induce ROS to high levels
when sufficient drug is present, and succumb to cell death upon
relatively short elesclomol treatment. We also reveal the
importance of an active ETC in both systems.
Our data indicate the lack of a unique protein ‘‘target’’ of
elesclomol. While the analysis of the heterozygous deletions
identified a single sensitive strain, nus1, its sensitivity was modest
compared to other drug-target strain combinations we have
analyzed in the past [12,24], and it is therefore unlikely that the
interaction of elesclomol and NUS1p, if any, is responsible for the
primary cytotoxic activity of elesclomol in the cell.
In contrast, the analysis of the homozygous deletion set
identified a robust and biologically coherent set of activities
associated with mitochondrial activities. Both manual and
computational (GSEA) analyses identified overlapping classes of
genes involved in various elements of electron transport,
mitochondrial translation (including mitochondrial ribosome
subunits, translation factors, tRNAs, and mRNA splicing en-
zymes), mitochondrial copper availability and homeostasis, and
genes involved in stress responses, particularly oxidative stress.
Importantly, equally sensitizing mutations were found distributed
throughout the ETC or its associated processes. Sensitive strains
containing mutations affecting individual subunits of the various
ETC complexes were identified, as were components required for
the modification or assembly of the complexes. Given that each of
the complexes contain numerous subunits, it is likely that most of
these mutations would not completely abrogate ETC function, but
more likely, only partially interfere with its activity. A similar
argument can be made for the sensitizing mutations affecting
mitochondrial translation, which produces a minority of the
proteins required for ETC function. Individually, these mutations
would likely only have a small effect on the overall translation
capability in the organelle, again perturbing but not eliminating
ETC activity. Thus, it appears that modulating the electron flow at
any of numerous points along the ETC can lead to enhanced
elesclomol impact on the cell and therefore, we conclude that it is
the disruption of the process of electron flow down the ETC,
rather than disruption of a particular protein or activity, that is of
relevance.
This effect on cell viability via ETC disruption appears to
operate similarly in human cells. In the data presented in Figure 4,
we used a second drug in combination with elesclomol rather that
a potentially sensitizing gene disruption and obtained analogous
results. Co-treatment of melanoma cells with elesclomol-Cu and
either of two ETC inhibitors enhanced cytotoxicity. Again, the
modulation of the process, rather than the inhibition of a
particular protein, seems paramount for increased elesclomol
activity.
The primary cytotoxic effect of elesclomol appears to be
confined to the mitochondria and not to involve a cytoplasmic
component. For example, none of the genes normally involved in
the response to cytoplasmic oxidative stress were identified in
the screen. This includes the YAP1 gene, which encodes the
transcription factor that is the primary responder to oxidative
stress in the cytoplasm and drives the up-regulation of a battery of
stress response genes. Deletion of another prominent cytoplasmic
stress response protein, superoxide dismutase 1 (SOD1p), actually
provided slight resistance to the elesclomol treatment. Deletion of
the copper chaperone protein CCS1p, required for SOD1p
activity, also provided mild resistance, thereby confirming the
result. In striking contrast, deletion of SOD2, the mitochondrial
superoxide dismutase, was highly sensitizing.
Elesclomol is thought to kill cells by inducing ROS to levels
from which the cell cannot recover. Given that the principal site of
action for elesclomol is likely the respiring mitochondrion, we
undertook experiments utilizing human cells lacking their
mitochondrial genomic DNA to examine ROS production and
cytotoxicity of the drug in cells that cannot undergo oxidative
phosphorylation. The human mitochondrial genome encodes 13
proteins, all of which are subunits of the various ETC complexes.
The absence of all 13 subunits, as is the case in the melanoma cells
used here (HBL-r0), ablates ETC function. These cells, when
treated with elesclomol-Cu, failed to induce ROS or apoptosis.
The parental cell line, with its ETC functions intact, responded
with potent ROS induction and cell death. Thus, elesclomol-
mediated ROS production and apoptosis are tightly linked,
confirming previous analyses [1]. With the current studies, we
can now propose the origin of this cascade is in the mitochondrion.
Figure 5. Mitochondrial DNA depleted (r0) melanoma cells are
resistant to ROS generation and cell death upon elesclomol-Cu
exposure. (A) HBL and HBL-r0 cells were treated for 12 h with
elesclomol-Cu (300 nM). At the end of the incubation, cells were stained
with hydroxyethidium to assess ROS levels by flow cytometry. Data are
representative of three independent experiments. (B) HBL and HBL-r0
cells were treated with 300 nM elesclomol-Cu or Cu for 24 h and cell
death determined using propidium iodide staining and flow cytometry.
doi:10.1371/journal.pone.0029798.g005
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normal cells as well. Complexes I and III are prone to electron
leakage, leading to the production of highly toxic superoxide or
hydroxyl radicals in the vicinity of the ETC [30]. Under most
conditions these free radicals are kept in check by the anti-oxidant
systems in the organelle. However, this basal level of electron
leakage can be amplified by inhibitors of electron chain complexes,
such as rotenone (complex I), antimycin A (complex III) or cyanide
(complex IV), leading to decreased viability [31]. Similarly, the
impact of elesclomol-Cu appears to overwhelm the oxidative stress
response systems, allowing cytotoxic levels of ROS to accumulate.
When the ETC inhibitors and elesclomol are used together during
treatment, a degree of synergy is observed indicating that the
combination of these drugs augments their effects in the cell as
compared to monotherapy.
How might elesclomol-Cu instigate this lethal increase of ROS
via its interaction with the ETC? A major clue comes from
elesclomol’s requirement for copper for its activity. Copper binds
to elesclomol in the Cu(II) state. In the cell, elesclomol-Cu can
undergo a redox reaction with copper being reduced to the Cu(I)
state. By itself, this reaction could produce free radicals by a
Fenton reaction. The redox potential for this reaction is 2330 mV
[7] and this potential appears critical for elesclomol activity.
Analysis of analogs with similar structures but with different
potentials has shown that only those compounds with potentials
similar to elesclomol-Cu are cytotoxic [7]. Very interestingly, this
potential is well aligned with the potential drops along the ETC
[32].
Considering all of these features, there appears to be at least
three major avenues by which elesclomol-Cu could lead to
heightened levels of ROS. The drug could generate ROS on its
own via its copper-based redox chemistry (perhaps using electrons
or redox potential ‘‘stolen’’ from the ETC). Alternatively, the drug
could interfere with the electron flow along the ETC, leading to
elevated levels of electron leakage and free radical formation
normally seen in cells, but here at levels that overwhelm the cell’s
defense systems. Finally, elesclomol-Cu could specifically interfere
with copper-requiring events associated with ETC function. Some
of the complexes are comprised of subunit proteins that require Cu
for their activity and their assembly depends on specific copper
chaperone proteins. Elesclomol could compete for or interfere with
these processes, thereby impacting electron flow down the chain.
These mechanisms are not mutually exclusive and, in fact, more
than one may come into play sequentially: the initial impact of
elesclomol-Cu could alter the subsequent dynamics of the ETC
allowing additional mechanisms to take place that ultimately result
in apoptosis. Whichever mechanism is used, we expect that the
match of the redox potentials within the ETC to that of
elesclomol-Cu is an important driving force.
The ability of elesclomol treatment to quickly lead to cell death,
and not just cell arrest, is an important feature of the drug. Drugs
that cause cidality are relatively uncommon in yeast, with fewer
than 10% of 10,000 drugs that inhibit growth inducing cidality
[26]. Both yeast and human cells exposed to elesclomol-Cu for a
few hours or less (Figures 1 and 5) are destined to die. The ability
to kill a cell exposed briefly to the drug is a valuable property for
an anticancer agent.
Finally, the improved mechanistic understanding of elesclomol’s
activity provided by this report has important implications for its
therapeutic application in oncology. Specifically, lactate dehydro-
genase (LDH) has been identified as a potential biomarker
predictive of response in the clinical evaluation of elesclomol. In
a Phase 3 trial of elesclomol in combination with paclitaxel, the
primary endpoint of progression free survival was achieved in
metastatic melanoma patients exhibiting low and normal LDH
levels in their bloodstream, with a significant improvement in
median progression free survival time. Conversely there was no
benefit in the elevated LDH population [6]. High serum levels of
LDH are thought to reflect a tumor burden with increased
reliance on glycolysis for its metabolic needs [33,34]. Conversely,
patients with lower LDH levels should have tumor burdens that
are more reliant on oxidative phosphorylation, a situation we have
shown here to be more sensitive to elesclomol treatment. Thus, the
insights established here by our studies on yeast and human cells
provide critical understanding into the clinical activity of the drug.
It also offers a compelling rationale for a biomarker-based
prioritization of patients likely to respond to elesclomol treatment.
Materials and Methods
Reagents
Elesclomol and elesclomol-copper complexes were synthesized
at Synta Pharmaceuticals Corporation. Copper chloride, anti-
mycin A and rotenone were all purchased from Sigma-Aldrich (St.
Louis, MO).
Yeast Strains
All strains used in this study are diploid and congenic with the
reference strain BY4743 (MATa/a his3D1/his3D1 leu2D0/
leu2D0 lys2D0/LYS2 MET15/met15D0 ura3D0/ura3D0).
Minimum Inhibitory Concentration (MIC) and Cidality
Determination
MIC determination was performed as previously described [9].
To test for cidality, wild type yeast (BY4743) were inoculated into
YPD at an OD600 of 0.5 such that they were in the mid-log phase
of growth. 100 ml of cells in media were aliquoted into wells of a 96
well plate, and a titration of elesclomol-Cu was added at a final
concentration ranging from 5 nM to 5 mM in DMSO or with 2%
DMSO to serve as a vehicle control. Cells were removed at hourly
intervals using a pin tool to transfer 5 ml of cells in media onto agar
dishes without drug. This transfer effectively dilutes the drug below
inhibitory concentrations. Plated cells were incubated at 30uC for
48 h and photographed. In this assay each single viable cell
transferred is able to form a visible colony. Concentrations and
doses that produced no viable colonies after 48 h were scored as
cidal.
Deletion Pool Growth and Chip Experiments
Screens were performed essentially as described by Ericson et al.
[35]. The BY4743 strain was used to determine the dose of
compound that resulted in 15% growth inhibition. Cells were
inoculated at an OD600 of 0.0625 in serial dilutions of drug and
grown in a Tecan GENios microplate reader (Tecan Systems Inc.,
San Jose, CA) at 30uC with orbital shaking. Optical density
measurements (OD600) were taken every 15 minutes until the
cultures were saturated, and the doubling time (D) was calculated
as described [19,36].
For genome-wide fitness profiles, ,4800 homozygous deletion
strains and ,1200 essential heterozygous deletion strains were
assayed as previously reported [35] prior to genomic DNA
extraction. 200 ng of genomic DNA were added to 2 separate
PCR reactions, one each with primers designed to amplify all
UPTAGs or all DOWNTAGS. One primer in each reaction was
biotinylated such that it could be detected following hybridization
to the chips using streptavidin-phycoerythrin. Intensity values for
the probes on the chip were extracted using the GeneChip
Operating Software (Affymetrix). Quantile normalization, outlier
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previously described [19]. The larger the ratio, the more depleted
(sensitive) is the strain as compared to control condition without
the drug.
Analysis of Elesclomol Sensitivity in Yeast Deletion
Mutants
The homozygous and heterozygous deletion strains were treated
en masse with 300 or 400 nM elesclomol-Cu, producing ,15%
growth inhibition. Each screen was performed in triplicate at both
drug concentrations. Because all six sets of data yielded similar
results, the log2 ratios from all of them were averaged. This
averaged data were used for subsequent analysis.
Gene-set Enrichment Analysis (GSEA)
Strains in the chemogenomic profile of elesclomol were mapped
to genes using chromosomal feature data downloaded from the
Saccharomyces Genome Database (http://www.yeastgenome.org)
and the resulting profile was analyzed by GSEA v2.07 in pre-
rank mode (Java implementation). All default parameters were
used except that the minimum and maximum gene set sizes were
restricted to 5 and 300, respectively. Biological process and protein
complex gene annotations were obtained from Gene Ontology
(http://berkeleybop.org/goose). Additional protein complex an-
notations based on consensus across different studies were
obtained from Benschop et al. [37]. The enrichment map was
generated with the Enrichment Map Plugin v1.1 [38] developed
for Cytoscape [39]. All default parameters were used. The nodes
in the map were clustered with the Markov clustering algorithm
[40], using the overlap coefficient computed by the plugin as the
similarity metric (coefficients less than 0.5 were set to zero) and an
inflation of 2. For each cluster, the leading edge genes were
computed as in [25] for each member node.
Multiple Drug Effect Analysis
Hs294T melanoma cells were purchased from American Type
Culture Collection (Manassas, VA) and cultured according to
standard techniques at 37uC in 5% (v/v) CO2 in DMEM plus
10% FBS. The half maximal inhibitory concentration (IC50) values
for elesclomol, rotenone and antimycin A in Hs294T cells were
determined using a 1.5-fold serial dilution series of each
compound. For combinatorial analysis, cells were plated in
triplicate for 24 h prior to the addition of drug or vehicle (0.3%
DMSO) to the culture medium. Combinations of elesclomol with
rotenone or antimycin A were performed concurrently based on
the IC50 and IC20 values for each agent. At 72 h, metabolic
activity was monitored by alamarBlue (Invitrogen, Carlsbad, CA)
fluorescence (560EX/590EM nM) with a SpectraMax microplate
reader (Molecular Devices). The resulting data were used to
calculate cell viability, normalized to vehicle control. Results were
fit to a four parameter logistic model (XLFit, ID Business
Solutions). Combinatorial effects were additionally analyzed using
the Chou and Talalay Median Effect method [28] to determine
combination index (CI) values.
Cytofluorometric analyses of r0 Melanoma Cell Lines
HBL and respiration-deficient HBL-r0 melanoma cells [29]
were cultured at 37uC in a humidified atmosphere containing 5%
CO2 in RPMI 1640 medium supplemented with 10% FCS, 2 mM
L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin and
2 g/l glucose. HBL-r0 cells were routinely maintained in medium
containing ethidium bromide, although the dye was removed 48 h
before the cells were used in experiments.
For ROS assessment, HBL and HBL-r0 cells were treated with
elesclomol-Cu (300 nM) for 12 h and superoxide production within
the mitochondria was determined using 1 mM hydroxyethidium, as
previously described [41]. Oxidized ethidium fluorescence was
analyzed on a FACS Canto cytofluorometer equipped with the
FACS Diva software 6.1 (Becton Dickinson, San Diego, CA). For
viability assays, HBL and HBL-r0 cells were incubated with
300 nM elesclomol-Cu or Cu for 24 h. Cell death was determined
using propidium iodide (5 mg/ml in PBS) staining and FACS
analysis. Inner mitochondrial transmembrane potential was mea-
sured by incubating cells (25610
4/ml) with 40 nM DIOC6(3) for
15 minutes at 37uC immediately prior to flow cytometry.
Supporting Information
Figure S1 Competitive growth assay and complemen-
tary whole-genome population genomics in S. cerevisiae.
For fitness profiling, deletion strains (heterozygotes and homozy-
gotes) are first pooled at approximately equal abundance. The
pool is then grown competitively in the presence or absence of
drug, its genomic DNA recovered en masse, and the DNA
barcodes PCR-amplified in two reactions (to amplify separately
the UPTAG and DOWNTAG barcodes from each strain). The
PCR products are hybridized to a tag array that contains the
barcode complements (5 copies of each are present on each chip),
and tag intensity is used to determine changes in the amount of
each strain present. Strains with deletions in genes that are
important for survival during drug treatment will be underrepre-
sented in the treated sample compared to the control. These genes
are either the target of the drug (if the gene is essential) or
components of critical pathways influencing the activity of the
drug (if the genes are non-essential). Figure modified from Fleming
et al. [9].
(TIF)
Figure S2 Combinatorial activity of elesclomol-Cu with
ETC inhibitors in Hs924T melanoma cells. Normalized
isobolograms for the concurrent treatment of elesclomol-Cu
with antimycin A (left panel) or rotenone (right panel) in Hs924T
melanoma cells using non-constant ratios. Combination Index (CI)
values were calculated using Median Effect analysis [28]. A point
in the isobologram represents the effect of a combinatorial drug
treatment. The further a point lays from the additive line, the
stronger the (synergistic or antagonistic) impact of the combina-
tion. The respective drug concentrations (in nM) for each
combination shown are as follows. For the elesclomol-Cu/
antimycin A combination: point 1, 5/14; point 2, 5/28; point 3,
5/56; point 4, 10/14; point 5, 10/28; point 6, 10/56. For the
elesclomol-Cu/rotenone combination: point 1, 5/21.5; point 2, 5/
43; point 3, 5/86; point 4, 10/21.5; point 5, 10/43; point 6, 10/
86.
(TIF)
Table S1 Growth responses of individual mutant
strains to treatment with elesclomol. Sub-MIC doses of
300 or 400 nM elesclomol-Cu were used to treat en masse the
collection of deletion strains as described in the Materials and
Methods. Three biological replicates were performed at each dose.
An analysis of the fitness data (the log2 ratio of the normalized
strain signal in treatment vs. DMSO control) showed that the
results were similar for both drug concentrations, so all six datasets
were combined by averaging the log2 ratios to yield the single set
of responses reported in the Table. These averaged fitness values
were used for all analyses presented in the paper.
(XLSX)
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